Search jobs 01-Jun-2021 Heartseed and Novo Nordisk enter into global collaboration and licence agreement for stem cell-based therapy for heart failure
Bagsværd
, Denmark and Tokyo, Japan, 1 June 2021 – Heartseed Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive worldwide collaboration and licence agreement for development, manufacturing and commercialisation of Heartseed’s lead asset HS-001.
HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC), which is currently under development by Heartseed for the treatment of heart failure.
Heartseed is planning to initiate a phase 1/2 clinical trial in Japan (LAPiS Study) in the second half of 2021 evaluating the safety and efficacy of HS-001 for the treatment of heart failure caused by ischemic heart disease. Japan’s Pharmaceutical and Medical Devices Agency has approved Heartseed
May 10, 2021
Six years ago, Atsushi Nakanishi launched Triple W with nothing but the seed of an idea and an overwhelming passion to realize it. Today, the startup is the creator and seller of DFree the world’s first wearable device for urinary incontinence.
The tiny, noninvasive device uses ultrasound to monitor the volume of urine in the user’s bladder in real time. When the bladder reaches its threshold, DFree sends an alert to the user’s smartphone to tell them it is time to go to the bathroom.
Nakanishi credits the ground-breaking product to a eureka moment in 2013. Due to uncontrollable diarrhea, he soiled himself in the street and, not long after, he learned that sales in Japan of adult diapers had surpassed that of baby diapers. Seeing both the need and demand for a product that lets people know when to use the bathroom, he “felt inspired” despite having zero medical background.
May 10, 2021
Six years ago, Atsushi Nakanishi launched Triple W with nothing but the seed of an idea and an overwhelming passion to realize it. Today, the startup is the creator and seller of DFree the world’s first wearable device for urinary incontinence.
The tiny, noninvasive device uses ultrasound to monitor the volume of urine in the user’s bladder in real time. When the bladder reaches its threshold, DFree sends an alert to the user’s smartphone to tell them it is time to go to the bathroom.
Nakanishi credits the ground-breaking product to a eureka moment in 2013. Due to uncontrollable diarrhea, he soiled himself in the street and, not long after, he learned that sales in Japan of adult diapers had surpassed that of baby diapers. Seeing both the need and demand for a product that lets people know when to use the bathroom, he “felt inspired” despite having zero medical background.
Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021: Methods of Commercializing iPSCs are Diverse and Continue to Expand
April 13, 2021 06:13 ET | Source: Research and Markets Research and Markets Dublin, IRELAND
ResearchAndMarkets.com s offering.
The main objectives of this report are to describe the current status of iPSC research, patents, funding events, industry partnerships, biomedical applications, technologies, and clinical trials for the development of iPSC-based therapeutics.
Since the discovery of induced pluripotent stem cells (iPSCs) a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The main objectives of this report are to describe the current status of iPSC research, patents, funding events, industry partnerships, biomedical applications, technologies, and clinical trials for the development of iPSC-based therapeutics.
Since the discovery of induced pluripotent stem cells (iPSCs) a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number.